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AbStrACt
Burning mouth syndrome (BMS) is defined as a burning sensation in the tongue or in any other region of the oral mu-
cosa, in the absence of specific oral lesions. The present study reviews the pharmacological treatments used in the last 10 
years to reduce the symptoms of BMS, and assesses the efficacy and safety of pharmacological interventions destined to 
alleviate the symptoms of BMS. To this effect, searches were made in the following databases: Micromedex®, Cochra-
ne Database® and PubMed®, crossing the following key words: drug, treatment, clinical trial, pain management, and 
burning mouth syndrome. The searches were limited to articles published in the last 10 years in English or Spanish, and 
involving human subjects. The searches were conducted in November 2006. The literature contains clinical studies in 
which BMS has been treated with drugs belonging to different pharmacological groups: antidepressants, antipsychotics, 
antiepileptic drugs, analgesics and mucosal protectors, among others. Although effective therapies have been identified 
in concrete cases, a treatment modality offering efficacy in most cases of BMS remains to be established. It is essential 
to gain further insight to the physiopathological mechanisms of BMS, and to establish differential diagnostic criteria to 
develop drugs with improved efficacy and safety profiles in the treatment of BMS.
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rESUMEN
El Síndrome de Boca Ardiente  (SBA) se define como una sensación de ardor o quemazón en la lengua o en cualquier 
otra localización de la mucosa oral en ausencia de lesiones bucales específicas. El presente artículo revisa los tratamientos 
farmacológicos utilizados en los últimos diez años para reducir la sintomatología del SBA y trata de objetivar la eficacia 
y seguridad de cualquier intervención farmacológica encaminada a aliviar los síntomas del SBA. Para ello se realizaron 
búsquedas en las bases de datos: Micromedex®, Cochrane Database® y Pubmed® cruzando las palabras: drug, treat-
ment, clinical assay, pain management y burning mouth syndrome. Se establecieron como límites en la búsqueda los 
artículos publicados en los últimos 10 años, en inglés o español y los estudios realizados en humanos. Las búsquedas 
fueron realizadas en noviembre 2006. En la literatura encontramos estudios clínicos en los que el SBA se ha tratado con 
fármacos enmarcados en diferentes grupos farmacológicos: antidepresivos, antipsicóticos, antiepilépticos, analgésicos 
y protectores de la mucosa entre otros. Aunque se han encontrado tratamientos eficaces en casos particulares, se sigue 
buscando un tratamiento que resulte eficaz en la mayoría de los casos. Es indispensable profundizar en los mecanismos 
Indexed in: 
-Index Medicus / MEDLINE  /  PubMed            
-EMBASE, Excerpta Medica
-SCOPUS
-Indice Médico Español                                                        
-IBECS
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INtrODUCtION
Burning mouth syndrome (BMS) is characterized by pain or 
burning sensation affecting an apparently healthy oral mu-
cosa and that cannot be attributed to other disorders such 
as candidiasis or irritation caused by dentures. According to 
Bergdahl and Bergdahl (1), the syndrome affects 3.7% of the 
general population, and is more common in women (5.5%) 
- particularly after menopause - than in men (1.6%).
The etiopathogenesis of BMS is not known, though different 
psychological and biological factors have been implicated. In 
effect, the psychological component is important in patients 
with BMS. Problems such as depression and anxiety play an 
important role in modulating pain perception, and are able 
to increase or decrease nerve transmission from the periphe-
ral pain receptors and thus modify individual perception of 
the pain. Consequently, treatment has been provided in the 
form of antidepressants among patients with BMS (2,3). 
On the other hand, the identification of sensory alterations 
in patients with BMS also suggests the existence of a bio-
logical basis related to alterations of both the central and 
peripheral nervous system (4). The peripheral alterations 
could be related to the density of the membrane receptors 
present in the oral mucosa, or to alterations in their reactive 
capacity - largely influenced by BMS risk factors such as 
stress, anxiety, the female sex, climacterium and old age (5). 
This theory is reinforced by the apparent topical action of 
clonazepam in the treatment of BMS (6,7). Gruskha and 
Bartoshuk suggested that BMS represents phantom pain 
caused by damage to the taste sensory system of susceptible 
individuals (8). Other authors have shown patients with BMS 
to suffer sensory alterations such as changes in heat tolerance, 
hypogeusia and dysgeusia, and increased excitability of the 
palpebral reflex, related to dysfunction of the dopaminergic 
system at central nervous system (CNS) level (4). Such dys-
function would comprise reduced dopaminergic inhibition 
and thus increased neuron excitability. Dysfunction of the 
dopaminergic system would justify systemic administration 
of  the antiepileptic drugs gabapentin and clonazepam, 
which act upon the gabaergic system - enhancing its activity 
in an attempt to counter dysfunction of the dopaminergic 
system. On the other hand, it was seen that BMS shares a 
series of characteristics with other chronic pain syndromes. 
This led to the application of drugs such as capsaicin (9,10) 
and benzidamine (11), which had been shown to be of use 
in application to such chronic pain syndromes.
A possible relationship has also been postulated between 
estrogen hormone imbalances (seen in menopause) and 
onset of the sensory alterations characterizing BMS. This 
subject has generated debate, due to the divergent results 
reported by the different studies made to assess the effects 
of hormone replacement therapy (HRT)(12-14).
Lastly, mention should be made of alterations in vascula-
rization as a possible cause of BMS (15).
At present there is no effective treatment applicable to most 
patients with BMS. The present study offers an exhaustive 
review of the pharmacological treatments used in BMS in 
the last 10 years.
In a first group, antidepressants were considered to be use-
ful in view of the known psychogenic component present 
in most cases of BMS. The antidepressants tested to date 
for the treatment of BMS have been trazodone in a double 
blind study, and paroxetine together with sertraline and 
the antipsychotic agent amisulpiride, in another simple 
blind study.
Tammiala-Salonen et al. (16) evaluated trazodone in a ran-
domized, double blind parallel group and placebo controlled 
trials with a duration of 8 weeks. During the first four days 
the patients received 100 mg of trazodone, followed by 100 
mg every 12 hours. Of the 37 patients included in the study, 
18 received trazodone and 19 placebo. Side effects of the 
medication led to the withdrawal of 7 patients in the trea-
ted group (39%) and two in the placebo group (11%). At 
the end of the study, 8 patients in the treated group (73%) 
reported improvement, two (18%) experienced no change, 
and one (9%) worsened. In the placebo group, 13 patients 
(76%) improved, and (24%) experienced no change. No 
differences in efficacy were observed between trazodone 
and placebo.
Maina et al. (17) compared the efficacy and tolerability of 
amisulpiride 50 mg/day, paroxetine 20 mg/day and sertraline 
50 mg/day, in the treatment of BMS, in the context of a 
randomized, simple blind study with a duration of 8 weeks. 
Following clinical and psychological evaluation, the patients 
were randomized to three groups (27 patients received ami-
sulpiride, 26 paroxetine and 23 sertraline). Before the end of 
the first week, 5 patients voluntarily abandoned the study 
due to a lack of efficacy or the appearance of adverse effects. 
None of these subjects belonged to the amisulpiride group. 
In addition, three patients failed to adhere to treatment as 
prescribed, and were removed from the study. The results 
showed an efficacy of about 70% after 8 weeks for the three 
types of treatment. The effect of amisulpiride manifested 
earlier, after a single week of therapy. There were no serious 
adverse effects in any of the three groups.
Antiepileptic drugs act in a way similar to gamma-amino-
butyric acid (GABA), enhancing its inhibitory effects upon 
the CNS, with a reduction in neuron excitability and pain. 
Among the antiepileptic drugs that have been used to treat 
BMS, mention should be made of clonazepam, evaluated 
in a number of  studies, and gabapentin - for which the 
literature yields a clinical case (18) and, very recently, an 
open-label study (19).
fisiopatológicos del SBA y establecer criterios diagnósticos diferenciales para poder desarrollar fármacos con mejor 
perfil de eficacia y seguridad en el tratamiento del SBA.
Palabras clave: Síndrome de boca ardiente, tratamiento, ensayos clínicos, casos clínicos, antidepresivos, analgésicos.
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Heckmann et al. (19) conducted an open study of 15 patients 
treated with gabapentin. The starting dose was 300 mg/day, 
and was increased at a rate of 300 mg every 48 hours to a 
maximum of 2400 mg/day. Seven patients were treated du-
ring two weeks, 6 patients during four weeks and another 
two patients during 6 weeks. Although two patients (13%) 
reported a three-point reduction in pain, and another two 
patients (13%) reported a decrease in two points on the 
visual analog scale (VAS) for pain, the authors concluded 
that gabapentin exerts little or no effect upon BMS.
Grushka et al. (20) in turn tested clonazepam via the oral 
route in a group of 30 patients with BMS. The starting 
dose was 0.25 mg/day, and was increased at a rate of 0.25 
mg/week, to a maximum of 3 mg/day, or until treatment 
response was elicited. The mean administered dose was 
1.1 ± 0.65 mg/day. Three groups were established, based 
on the recorded response to treatment: 13 patients (43%) 
experienced at least slight improvement and continued with 
the treatment; 8 patients (27%) experienced improvement 
but abandoned the treatment because of adverse reactions; 
and 9 patients (30%) reported no benefit. In the first group, 
most patients (61%) responded to a dose of 0.75 mg/day 
or lower.
Woda et al. (6) evaluated topical clonazepam in an open-
label study with 25 patients (80% of which were receiving 
antidepressive or anxiolytic therapy that was not suspended 
during the study). The patients were instructed to break up 
the clonazepam tablet and retain saliva in the mouth during 
three minutes, without swallowing - followed by expulsion. 
The administered dose was 0.5 to 1 mg, two or three times 
a day. Six patients (24%) experienced no improvement, 9 
patients (36%) reported partial improvement but continued 
with the treatment, and 10 patients (40%) reported complete 
symptoms remission. In these subjects the treatment was 
discontinued after one to three months, without subsequent 
symptoms relapse. In the patients not using drugs with ac-
tions upon the CNS, the results were comparatively better 
- though the differences were not statistically significant.
Posteriorly, the same authors improved the previous study 
(6) and carried out a randomized, double blind parallel 
group and multicenter survey comparing topical clona-
zepam (1 mg three times a day) versus placebo (7). They 
included 24 patients with BMS in each group and evaluated 
pain with a VAS before the start of the study. The patients 
were previously trained to break up the clonazepam tablet 
in the mouth and retain the saliva in contact with the pa-
inful points during three minutes. The pain was re-evalua-
ted 5 minutes after expelling the saliva with clonazepam. 
Initially, the treatment was planned to last 14 days, with 
administration three times a day - though measurements of 
clonazepam activity were also obtained after 6 months. Of 
the 22 patients who completed treatment with clonazepam, 
9 (41%) reported the medication to be very effective - with 
a 4-7 point reduction on the VAS. Seven patients (32%) 
reported partial improvement (2-3 points), and 6 patients 
(27%) experienced no improvement (three of these actually 
worsened despite treatment). Thirteen patients were evalua-
ted after 6 months of treatment with clonazepam: in 7 cases 
(54%) the treatment remained effective (with a pain score 
reduction of 2 or more points), while three patients (23%) 
recorded a pain reduction of under two points but claimed 
to feel better and wished to continue the treatment. Finally, 
three patients (23%) abandoned treatment due to a lack of 
efficacy or the appearance of drowsiness.
Analgesics have also been used to treat the symptoms of 
BMS. These drugs were selected in view of their usefulness 
in treating other chronic pain disorders (capsaicin) or other 
alterations of the oral mucosa involving pain (benzidamine 
hydrochloride).
Capsaicin 0.25% via the oral route was evaluated by Pe-
truzzi et al. (9) in a randomized, triple blind and placebo 
controlled study. Two groups of 25 patients with BMS were 
established. In the treated group it was seen that of the 15 
patients who initially presented VAS scores of 8-10, a full 14 
(93%) showed improvement. In turn, of the 8 patients with 
VAS scores of 4-7, five (63%) improved after one month of 
treatment with oral capsaicin 0.25%. In the placebo group, 
of the 13 patients with VAS scores of 8-10, none impro-
ved. In turn, of the 7 patients with VAS scores of 4-7, only 
one showed improvement. In relation to adverse effects, 
progressive cases of gastric pain were documented in the 
treated group - totaling 8 cases (32%) after four weeks of 
treatment. This limits the use of capsaicin via the systemic 
route in prolonged treatments.
Likewise, the literature presents a case of BMS treated with 
topical capsaicin (19). This corresponded to a 59-year-old 
woman with a three-year history of BMS, and a VAS pain 
score of  10. The symptoms prevented her from eating, 
and she moreover wore dentures. Treatment for BMS with 
diluted Tabasco sauce was proposed: initially 1-2 drops in 
60 ml of warm water, four times a day, followed by gradual 
dose escalation. After 6 weeks using a solution of 16 drops 
of Tabasco sauce in 60 ml of water, the patient reported 
pain relief. After 8 months, she claimed the pain intensity 
to have decreased 50%, and after 10 months using undiluted 
Tabasco sauce, she reported a 2-point pain score on a scale 
of 10 points (i.e., practically no pain).
Sardella et al. (11) carried out a randomized, double blind 
study to assess the efficacy and safety of  benzidamine 
hydrochloride in the treatment of BMS. Three groups were 
established: the first received 15 ml of benzidamine hydro-
chloride 0.15% as a rinse for one minute, three times a day 
during four weeks; the second group received 15 ml of a 
placebo solution; and the third group received no treatment. 
In the treated group, 90% of the patients failed to improve, 
while 10% reported partial improvement. In the placebo 
group the corresponding percentages were 80% and 20%, 
respectively, while in the third group 90% of the patients 
failed to improve, and 10% actually worsened. The statistical 
analysis revealed no differences among these three groups.
Sucralfate was selected by Campisi et al. (21), on the grounds 
that it protects the digestive mucosa. The objective was 
to determine whether this protective effect could also be 
extended to the oral mucosa.
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The authors carried out a study to determine the efficacy 
of sucralfate in application to BMS, in two pharmaceutical 
forms. They established two groups of 7 patients each: the 
first group received a 20% suspension of sucralfate four 
times a day during three weeks, while the second group 
received chewable tablets containing 1 g of sucralfate, with 
the same dosing regimen as in the other group. After three 
weeks of treatment, and in the first group, three patients 
(42%) reported symptoms improvement; two patients (29%) 
experienced no improvement; and another two patients 
(29%) had worsened. In the second group, two patients 
(29%) improved; three patients (42%) showed no change; 
and two patients (29%) worsened.
Femiano et al. (22) evaluated alpha-lipoic acid (ALA) at a 
dose of 600 mg/day, in a parallel group and placebo con-
trolled study. ALA was selected because of its neurological 
regenerative properties, demonstrated in the treatment of 
diabetic neuropathy - a disorder with features similar to 
BMS and involving chronic pain. In the treated group (n 
= 48), 5 patients (10%) experienced slight improvement, 19 
patients (40%) reported clear improvement, and 15 patients 
(31%) showed resolution of their BMS. Eighty-one percent 
of the treated patients experienced some degree of improve-
ment. In comparison, in the placebo group, only 6 patients 
(13%) experienced only mild improvement. After 6 months, 
19 of the patients (49%) who had experienced improvement 
after two months of treatment with ALA worsened. The 
same authors have published other studies of ALA under 
different conditions (23-26).
DISCUSSION
A review has been made of the articles and clinical cases 
published in the literature between 1996 and 2006, describing 
different pharmacological options for the treatment of BMS. 
The data relating to the efficacy and safety of each of the drugs 
used in the different studies are summarized in Table 1.
AUTHOR DRUG HEALIN IMPROVEMENT 
Tammiala-Salonen et al. (16) Trazodone 
1 0% 73% 
Maina et al. (17) Amisulpiride, Paroxetine, Sertraline 0% 70% 
Heckmann et al. (19) Gabapentin 0% 33% 
Grushka et al. (20) Systemic clonazepam 
3 0% 43% 
Woda et al. (6) Topical clonazepam 
4 40% 36% 
Gremeau-Richard et al. (7) Topical clonazepam 41% 32% 
Petruzzi et al. (9) Capsaicin
5 0% 83% 
Sardella et al. (11) Benzidamine 
6 0% 10% 
Campisi et al. (21) Sucralfate 0% 36% 
Femiano et al. (22) Alpha-lipoic acid 
7 31% 50% 
1- In the placebo group, 76% of the patients improved. Adverse reactions were 
2- observed in 39% of the patients in the treated group and in 11% of the subjects 
3- administered placebo. 
4- Earlier effects were recorded for amisulpiride. 
5- Adverse reactions were recorded in 27% of cases. 
6- The healed cases did not suffer relapses. 
7- Adverse reactions were recorded in 32% of cases. 
8- In the placebo group, 20% of the patients experienced improvement. 
9- After 6 months, 49% of the patients with initial improvement were seen to worsen. 
table 1. Efficacy and safety of the drugs used to treat the symptoms of burning mouth syndrome 
(BMS).
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In view of  the results obtained, it can be affirmed that 
capsaicin and clonazepam, administered systemically via 
the oral route, can be discarded because of their adverse 
reactions. Gabapentin has not shown efficacy. While al-
pha-lipoic acid appears useful, it loses efficacy over time. 
Benzidamine and trazodone have not been shown to be 
more effective than placebo in the treatment of BMS, and 
trazodone moreover generates an important number of 
adverse effects. With amisulpiride, paroxetine, sertraline and 
sucralfate, the patients reported improvement - though the 
study designs were deficient. Topical clonazepam presently 
seems to be the best option, with healing of almost half  of 
all patients (40%).
However, the clinical trials conducted to date are not par-
ticularly robust. Most are open-label uncontrolled studies 
involving small patient samples, short periods of time, and 
in only half  of the cases are treatments compared versus 
placebo (Table 2). Furthermore, expression of the results 
is heterogeneous. In this sense, it would be interesting to 
homogenize criteria for expressing the results obtained (27). 
Numerous etiological factors have been cited, including local 
problems such as salivary alterations, systemic disorders, 
and psychopathological alterations (27,28). The population 
most commonly expressing BMS, i.e., individuals with psy-
chological or psychiatric problems and the polymedicated 
population, is often excluded from the trials (29).
Although effective therapies have been identified in concrete 
cases, a treatment modality offering efficacy in most cases of 
BMS remains to be established. It is essential to gain further 
insight to the physiopathological mechanisms of BMS, and to 
establish differential diagnostic criteria to develop drugs with 
improved efficacy and safety profiles in the treatment of BMS.
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